Zealand Pharma A/S (CPH:ZEAL)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 32.11B |
| Revenue (ttm) | 55.69M |
| Net Income (ttm) | -1.19B |
| Shares Out | 70.69M |
| EPS (ttm) | -17.26 |
| PE Ratio | n/a |
| Forward PE | 5.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 348,059 |
| Average Volume | 571,539 |
| Open | 460.90 |
| Previous Close | 454.20 |
| Day's Range | 454.50 - 472.00 |
| 52-Week Range | 380.20 - 972.00 |
| Beta | 0.56 |
| RSI | 55.67 |
| Earnings Date | May 8, 2025 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
Financial Performance
In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.
Financial StatementsNews
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome
Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Z...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...
European stocks edge higher after Trump delays 50% tariffs on EU
European shares traded in positive territory on Monday.
European stocks recover after Trump delays EU tariffs in hopes of deal
European shares kicked off the week on a positive note on Monday, recouping the previous session's losses, as markets heaved a sigh of relief after U.S. President Donald Trump delayed his threat to im...
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer...
Zealand: Promising Roche-Partnered Obesity Drug Developer - But Stock Is Pricey
Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF market potential and challenges.
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-n...
Zealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call Transcript
Zealand Pharma A/S (OTCPK:ZLDPF) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsAdam Lange - Vice President, Investor...
Zealand Pharma announces closing of collaboration and license agreement with Roche
Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand...
Zealand Pharma A/S 2025 Q1 - Results - Earnings Call Presentation
Zealand Pharma Announces Financial Results for the First Three Months of 2025
Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabi...
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion dealto develop Danish biotechZealand Pharma's "next generation" weight loss drug.
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results
Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq C...
Zealand Pharma says obesity drug deal with Roche will help it stay independent
Danish biotech is developing petrelintide in partnership with the Swiss pharma group
Zealand Pharma gains as trial for Roche-partnered obesity drug starts
Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes
Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or obesit...
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPRE...
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as i...
Zealand Pharma (ZLDPF) Launches 2025 Incentive Program | ZLDPF Stock News
Zealand Pharma (ZLDPF) Launches 2025 Incentive Program | ZLDPF Stock News
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 10 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...
Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025
Company announcement – No. 9 / 2025 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025 Copenhagen, Denmark, April...
Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche
The Danish biotech's recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.
Resolutions from Zealand Pharma's Annual General Meeting 2025
Company announcement – No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no.
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NA...